期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

补充和替代医学在肠易激综合征治疗中的应用 被引量：2

Complementary and Alternative Medicine for Treatment of Irritable Bowel Syndrome
下载PDF
导出
摘要 肠易激综合征(IBS)是常见的肠道功能性疾病,近年来发病率呈上升趋势。目前由于常规医学疗法对IBS的疗效欠佳,补充和替代医学(CAM)在IBS治疗中的作用越来越受到关注,其中益生菌、薄荷油以及一些身心治疗如催眠疗法、认知行为治疗等对IBS的疗效已得到较普遍认可。本文就CAM在IBS治疗中的应用作一综述。 Irritable bowel syndrome （IBS） is a commonly seen functional gastrointestinal disorder and the incidence is increasing in recent years. Currently, due to the poor efficacy of conventional medical treatment, complementary and al- ternative medicine （CAM） has attracted more and more attention. Probiotics, peppermint oil and some psychosomatic ther- apies such as hypnotherapy, cognitive-behavioral therapy for the treatment of IBS are becoming the attractive options. This article reviewed the advances in study on CAM for treatment of IBS.
作者 杨焱 陈燕 张红杰
机构地区 南京医科大学第一附属医院消化内科
出处 《胃肠病学》 2012年第8期503-505,共3页 Chinese Journal of Gastroenterology
关键词 肠易激综合征 补充和替代医学 治疗 有益菌种 薄荷油 催眠术 认知疗法 Irritable Bowel Syndrome Complementary And Alternative Medicine Therapy Probiotics Pep-permint Oil Hypnosis Cognitive Therapy
分类号 R574 [医药卫生—消化系统]
  • 相关文献

参考文献32

  • 1肠易激综合征诊断和治疗的共识意见（2007，长沙）[J].中华消化杂志,2008,28(1):38-40. 被引量：431
  • 2Ernst E. Science and antiscience in complementary medicine[J]. Br J Hosp Med, 1995, 54: 504-305.
  • 3Wu JC. Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome : facts or myths [J]? Gastroenterol Hepatol (N Y), 2010, 6 (11): 705-711.
  • 4Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects [ J ]. Gastroenterology, 2007, 133: 24-33.
  • 5Caballero-Franco C, Keller K, De Simone C, et al. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells [ J ]. Am J Physiol Gastrointest Liver Physiol, 2007, 292 ( 1 ) : G315-G322.
  • 6Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors[J]. Nat Med, 2007, 13 (1): 35 -37.
  • 7Verdu EF, Bercik P, Bergonzelli GE, et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction [ J ]. Gastroenterology, 2004, 127 (3) : 826-837.
  • 8O' Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles [ J ]. Gastroenterology, 2005, 128 (3) : 541-551.
  • 9Hoveyda N, 1-Ieneghan C, Mahtani KR, et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome [ J ]. BMC Gastroenterol, 2009, 9: 15.
  • 10Brenner DM, Moeller M J, Chey WD, et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review [ J ]. Am J Gastroenterol, 2009, 104 (4) : 1033-1049.

二级参考文献19

  • 1袁耀宗,许斌,莫剑忠,王吉耀,李兆申.马来酸曲美布汀治疗肠易激综合征的疗效和安全性研究[J].胃肠病学,2005,10(3):143-147. 被引量：107
  • 2杨欣艳,李世荣.微生态制剂在肠易激综合征治疗中的作用[J].中华医学杂志,2005,85(39):2802-2804. 被引量：16
  • 3Saito YA, Schoenfeld, Locke GRI 3rd. The epidemiology of irritable bowel syndrome in North America: a systemic review. Am J Gastroenterol, 2002, 97 : 1910-1915.
  • 4Xiong LS, Chen MH, Chen HX, et al. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. Aliment Pharmarcol Ther, 2004, 19 : 1217-1224.
  • 5Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology, 2002, 123: 2108-2131.
  • 6Devaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut, 2002, 51(Suppl 1): i67-i71.
  • 7Drossman DA, Ringel Y, Vogt BA, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gasroenterology, 2003, 124:754-761.
  • 8Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut, 2004, 53:1096-1101.
  • 9Longstreth GF, Thompson WG, Chey WD. Functional bowel disorders// Drossman DA. Rome Ⅲ : the functional gastrointertinal disorders. 2006:487-555.
  • 10Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther, 1997, 11:553-559.

共引文献430

同被引文献34

  • 1Ringel-lmlka T, Palsson OS, Maier D, et al. Probiofic bacteria Lacto- bacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 ver- sus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study [J]. J Clin Gastroenterol, 2011, 45(6): 518-525.
  • 2Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal mi- crobiota of in'liable bowel syndrome patients differs simificantly from that of healthy subjects [Y]. Gastroenterology, 2007, 133: 24-33.
  • 3Caballero-Franco C, Keller K, Dc Simone C, et al. The VSL#3 pro- biotic formula induces mucin gene expression and secretion in co- lonic epithelial ceils [J. Am J Physiol Gasa'ointest Liver Physiol, 2007, 292(I): G315-G322.
  • 4Rousscaux C, Thuru X, Gelot A, ct al. Lactobacillus acidophilus modulates ivtcstinal pain and induces opioid and cannabinoid recep- tors [J]. Nat Med, 2007, 13(I): 35-37.
  • 5Hovcyda N, Heneghan C, Mahtani K_R, ct al. A systematic review and meta-analysis: probiotics in the a'eaUnent of irritable bowel syn- drome [.11. BMC Gasaz)cnterol, 2009, 9: 15.
  • 6Brenner DM, Moeller M J, Chcy WD, ct al. The utility of probiotics in the trcabncnt of irretabc bowel syndromc:a systematic review [Y]. Am J Gastroenterlol, 2009, 104(4): I033-I049.
  • 7Oerlemans S, van Cranenburgh O, Herremans PJ, et al. Intervening on cognitions nd behavior in irritable bowel syndrome:A feasibility trial using PDAs [J]. J Psychosom Res, 2011, 70(3): 267-277.
  • 8Lackncr JM, Gudlcski GD, kecfcr L, et al. Rapid response to cognitive behavior therapy predicts aeatment outcome in patients with irritable bowel syndrome [J]. Clin Gastroenterol Hepatol, 2010, 8(5): 426-432.
  • 9Reme SE, Kennedy T, Jones R, et al. Predictors of treatment out- come after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care [J]. J Psy- chosom Res, 2010, 68(4): 385-388.
  • 10Jones M, Koloski N, Boyce P, et al. Pathways connecting cognitive behavioral therapy and change in bowel symptoms oflBS [J]. J Psy- chosom Res, 2011, 70(3): 278-285.

引证文献2

二级引证文献17

胃肠病学
2012年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部